

## CHIMERIC THERAPEUTICS COMMENCES TRADING ON THE ASX

### HIGHLIGHTS

- Chimeric lists on the ASX today after receiving overwhelming support for its \$35m IPO at \$0.20 per share with an indicative market capitalisation of A\$66.1m
- Chimeric is a clinical stage cell therapy company focused on the development of novel cell therapies for oncology
- Developing CLTX-CAR T, which uses a peptide derived from scorpion toxin to direct T cells to target glioblastoma (brain cancer)
- Potent antitumor activity against glioblastoma established in preclinical models
- Phase 1 trial of CLTX-CAR T therapy currently underway at City of Hope cancer centre in Los Angeles, where the first patient was dosed in late 2020
- Chimeric owns the exclusive global rights to develop and commercialise City of Hope's CLTX-CAR T cells, as well as further develop the therapy for other cancers
- Widespread big pharma interest in the CAR T sector including large transactions at pre-clinical stage
- Chimeric recently announced an outstanding US-based executive team – Ms Jennifer Chow (COO) and Dr Syed Rizvi (CMO) – both bringing CAR T experience with leading players in the space
- Chimeric will use funds from the IPO for the phase 1 clinical trial of the CLTX-CAR T at City of Hope and to further develop an oncology focused pipeline of novel cell therapies
- The IPO was supported by joint lead managers Bell Potter and Baker Young

Chimeric Therapeutics (ASX:CHM, "Chimeric" or the "Company"), a drug development company focused on novel CAR T cell therapies for solid tumors, commences trading on the Australian Securities Exchange (ASX) today following the completion of an Initial Public Offering (IPO) that raised \$35 million from investors.

The offer comprised of 175 million shares to raise A\$35 million at an offer price of A\$0.20 per share, giving the Company a market capitalisation of A\$66.1m upon listing.

The IPO was met with excellent support from both new and existing institutional, professional and retail investors within Australia and overseas.

Chimeric is developing ground-breaking CAR T cell therapies for solid tumors based on scientific research conducted by leading US CAR T experts at the City of Hope (COH) Cancer Centre in Los Angeles. Chimeric has acquired the exclusive global rights to develop and commercialise its chlorotoxin (CLTX-)CAR T technology developed at the lab of two prominent CAR T researchers globally, Professors Christine Brown and Michael Barish. Professor Brown also Chairs Chimeric's Scientific Advisory Board.

Preclinical models have established potent activity against glioblastoma (GBM) from CLTX-CAR T cell therapy. GBM is the most common and aggressive type of brain tumor, with overall survival following first recurrence estimated to be just 5-8 months. CLTX is derived from scorpion toxin, which binds preferentially to unique targets on brain

cancer cells.

CLTX-CAR T cells do not target healthy cells and do not elicit adverse side effects when delivered intracranial and through IV routes in brain cancer mouse models, all while binding to a higher percentage of GBM tumors than immunotherapies against other targets.

The Phase 1 clinical trial of the CLTX-CAR T technology is currently underway, with the first patient being dosed in late 2020. Approximately 18 patients are expected to be part of the open label trial which is expected to be completed within 18-24 months, with first data expected in H2 2021.

CAR T cell therapy is attracting significant interest from big pharma, evidenced by recent large transactions at the pre-clinical stage.

Chimeric has attracted an outstanding US-based senior management team, announced just prior to lodgment of the IPO prospectus. Chief Operating Officer (COO) Ms Jennifer Chow joins Chimeric from Kite Pharmaceuticals, a cancer immunotherapy company with a primary focus on CAR T therapies, where she was Head of Global Marketing, Analytics and Commercial Operations. Ms Chow was also previously the Global Cell Therapy Commercial Lead at Celgene Corporation, a pharmaceutical company specialising in cancer and immunology drugs, where she pioneered the design and development of its global CAR T commercial strategy and operating model.

Chief Medical Officer (CMO) Dr Syed Rizvi joins Chimeric from Legend Biotech (Legend), a global clinical-stage, NASDAQ listed biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications. Dr Rizvi served as Vice President of Clinical Development, Medical Affairs & Clinical Sciences at Legend, where he led global co-development activities for Cilta-cel (JNJ4528), a B cell maturation antigen (BCMA)-directed CAR T cell therapy. Dr Rizvi was also formerly the Global Medical Affairs Head of Celgene Corporation's CAR T Program, where he was responsible for the global medical strategy for Celgene's CAR T assets.

The Company is Chaired by Australian biotech entrepreneur Paul Hopper, Executive Chairman & founder of Imugene Ltd (ASX:IMU), former Chairman of Viralytics (ASX:VLA, acquired by Merck in 2018 for A\$502m), and a Chairman, Director or CEO of more than fourteen companies in the US and Australia.

Chimeric will use funds from the IPO for the phase 1 clinical trial of the CLTX-CAR T at COH and to further develop an oncology focused pipeline of novel cell therapies. The proceeds will also be used to invest in personnel, admin/corporate and working capital, as well as license fees to COH.

"The team at Chimeric has been overwhelmed with the support for the IPO and what we believe is a highly promising technology in an attractive area of immuno-oncology," said Chimeric's Executive Chairman Paul Hopper.

"The IPO allows us to further develop the CLTX-CAR T therapy and extend it to patients with an unmet need, including those suffering from GBM as well as other solid tumors.

"We would like to thank our new and existing shareholders for their support and look forward to sharing in the growth of the business as we strive to deliver value via both clinical and commercial outcomes."

Bell Potter and Baker Young were Joint Lead Managers to the IPO.

**Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.**

## **ABOUT CHIMERIC THERAPEUTICS**

Chimeric Therapeutics is developing ground-breaking CAR T cell therapies for solid tumors based on scientific research conducted by leading US CAR T experts at the City of Hope (COH) Cancer Centre in Los Angeles. Its CLTX-CAR T technology incorporates chlorotoxin (CLTX), a peptide derived from scorpion toxin, as a novel CAR tumor recognition domain. This domain extends the range of CAR T cell targeting in solid tumors.

Potent antitumor activity against glioblastoma (GBM) has been established in preclinical models. Currently undergoing Phase 1 clinical trials in GBM at COH, CLTX-CAR T has significant drug administration benefits since it can be delivered during an outpatient visit.

CLTX-CAR T cells differ from other GBM-targeting immunotherapies by its specific and broad recognition of patient tumors and of the majority of cells within these tumors. CLTX-CAR T cells target GBM through recognition of a receptor complex composed of membrane-bound matrix metalloprotease 2 (MMP2) and involving the chloride channel CLC3.

CLTX-CAR T cells do not exhibit off-tumor recognition of normal human or murine cells/tissues in preclinical models, consistent with the documented safety of administering other CLTX-containing therapeutic agents in humans.

The CLTX peptide has also demonstrated safety and specificity in clinical testing as a radiotherapy delivery conjugate and as an imaging agent in fluorescence-guided surgery for recurrent/refractory GBM.

## CONTACT

### Investors

Paul Hopper

Executive Chairman

P: +61 406 671 515

E: paulhopper@lifescienceportfolio.com

W: www.chimerictherapeutics.com

### Media

Matthew Wright

NWR Communications

P: +61 451 896 420

E: matt@nwrcommunications.com.au